Janus Henderson Group PLC Kal Vista Pharmaceuticals, Inc. Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$12.36 - $18.28 $14.1 Million - $20.9 Million	-1,141,683 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$17.11 - $24.49 $477,659 - $683,687	-27,917 Reduced 2.39%	1,141,683 $19.9 Million
Q2 2021 Aug 16, 2021	BUY	$23.12 - $29.91 $828,343 - $1.07 Million	35,828 Added 3.16%	1,169,600 $28 Million
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $14.3 Million - $41.4 Million	973,261 Added 606.35%	1,133,772 $29.1 Million
Q4 2020 Feb 16, 2021	SELL	$12.88 - $19.47 $109,454 - $165,456	-8,498 Reduced 5.03%	160,511 $3.05 Million

Q3 2020 Nov 16, 2020	BUY	$9.83 - $13.99 $80,930 - $115,179	8,233 Added 5.12%	169,009 $2.13 Million
Q2 2020 Aug 14, 2020	BUY	$6.75 - $12.89 $57,165 - $109,165	8,469 Added 5.56%	160,776 $1.94 Million
Q1 2020 May 14, 2020	BUY	$5.8 - $18.56 $791,073 - $2.53 Million	136,392 Added 857.0%	152,307 $1.17 Million
Q4 2019 Feb 18, 2020	BUY	$10.31 - $17.81 $164,083 - $283,446	15,915 New	15,915 $283,000

130

46.5M

113K

72K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $290M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.